Document Detail

Epoprostenol in chronic thromboembolic pulmonary hypertension with distal lesions.
MedLine Citation:
PMID:  15554033     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Although patients with primary pulmonary hypertension and patients with chronic thromboembolic pulmonary hypertension with distal lesions may share similar pathophysiological characteristics, scarce information is available on the usefulness of epoprostenol in this form of secondary pulmonary hypertension. The aim of this study was to evaluate the feasibility, safety and efficacy of epoprostenol therapy in surgically untreatable patients with chronic thromboembolic pulmonary hypertension. METHODS: Continuous infusive therapy with epoprostenol was undertaken in 16 patients with primary pulmonary hypertension and in 11 surgically untreatable thromboembolic pulmonary hypertension patients. The median follow-up was 12.4 months (range 6-23 months). Patients underwent clinical, echocardiographic and hemodynamic evaluation at baseline and a 6-min walk test every 3 months after beginning epoprostenol; ultrasound evaluations were repeated in a subgroup of patients. RESULTS: Epoprostenol therapy improved the clinical status, exercise tolerance and NYHA functional class. A greater left ventricular end-diastolic volume was recorded at echocardiography in both groups. CONCLUSIONS: Epoprostenol therapy may be feasible, safe and clinically effective in patients with surgically untreatable chronic thromboembolic pulmonary hypertension.
Laura Scelsi; Stefano Ghio; Carlo Campana; Andrea Maria D'Armini; Alessandra Serio; Catherine Klersy; Franco Piovella; Mario Viganò; Luigi Tavazzi
Related Documents :
7040233 - Renovascular hypertension in black patients.
12775963 - Doxazosin as combination therapy for patients with stage 1 and stage 2 hypertension.
8244483 - Efficacy of amphotericin b in multi-drug resistant kala-azar in children in first decad...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Italian heart journal : official journal of the Italian Federation of Cardiology     Volume:  5     ISSN:  1129-471X     ISO Abbreviation:  Ital Heart J     Publication Date:  2004 Aug 
Date Detail:
Created Date:  2004-11-19     Completed Date:  2005-02-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100909716     Medline TA:  Ital Heart J     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  618-23     Citation Subset:  IM    
Division of Cardiology, IRCCS Policlinico San Matteo, Pavia, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / therapeutic use*
Echocardiography, Doppler
Epoprostenol / therapeutic use*
Exercise Tolerance
Feasibility Studies
Heart Catheterization
Hypertension, Pulmonary / complications,  drug therapy*
Infusions, Intravenous
Middle Aged
Platelet Aggregation Inhibitors / therapeutic use*
Regression Analysis
Thromboembolism / complications,  drug therapy*
Treatment Outcome
Reg. No./Substance:
0/Antihypertensive Agents; 0/Platelet Aggregation Inhibitors; 35121-78-9/Epoprostenol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Mechanisms and predictors of transient left ventricular dysfunction early after successful percutane...
Next Document:  Conotruncal heart defects: impact of genetic syndromes on immediate operative mortality.